Inactive Instrument

Company Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles Other stock markets
-	-

06-16	Lakefront Biotherapeutics NV commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on April 28, 2026.	CI
06-10	Lakefront Announces Share Buyback Program

Business description: Galapagos NV

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Sales by Activity: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Research and Development (R&D)	485M	505M	240M	276M	1.11B

See all business segments

Geographical breakdown of sales: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	2.11M	3.55M	16K	34.86M	-
United States of America	468M	414M	240M	241M	-

See all geographic segments

Executive Committee: Galapagos NV

Manager	Title	Age	Since
Henry Gosebruch CEO	Chief Executive Officer	53	12/05/2025
Aaron Cox DFI	Director of Finance/CFO	43	06/07/2025
Eric Hedrick CTO	Chief Tech/Sci/R&D Officer	61	07/06/2026
Robert Hughes CTO	Chief Tech/Sci/R&D Officer	-	31/12/2023
Sandra Cauwenberghs IRC	Investor Relations Contact	-	31/10/2020

See GALAPAGOS NV governance

Composition of the Board of Directors: Galapagos NV

Director	Title	Age	Since
Linda Higgins BRD	Director/Board Member	63	21/10/2019
Oleg Nodelman BRD	Director/Board Member	49	06/10/2024
Henry Gosebruch BRD	Director/Board Member	53	12/05/2025
Dawn Svoronos BRD	Director/Board Member	72	27/07/2025
Jane Griffiths BRD	Director/Board Member	71	27/07/2025
Neil G. Johnston BRD	Director/Board Member	-	31/10/2025
Devang Bhuva BRD	Director/Board Member	-	31/10/2025
Paulo Fontoura BRD	Director/Board Member	-	08/02/2026
Gino Santini CHM	Chairman	69	27/04/2026

Composition of the Board of Directors

Shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	477 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	205 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	132 M
De Grote Voskuil Capital BV 0.3794 %	250,000	0.3794 %	7 M
Saint Olive Gestion SNC 0.0645 %	42,500	0.0645 %	1 M

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	474 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	107 M
Madison Avenue Partners LP 5.472 %	3,606,203	5.472 %	102 M
Madison Avenue Partners LP 3.741 %	2,465,179	3.741 %	70 M
EcoR1 Capital, LLC 2.53 %	1,667,119	2.53 %	47 M

List of GALAPAGOS NV shareholders

Company details: Galapagos NV

Galapagos NV

Industriepark Mechelen Noord

2800, Mechelen

+32 1 534 29 00

http://www.galapagos.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.45%	+7.07%	-5.17%	+2.45%	46.2B
REVOLUTION MEDICINES, INC.	+0.29%	+12.35%	+406.36%	+610.49%	38.71B
IQVIA HOLDINGS INC.	+0.66%	+14.47%	+21.90%	-13.24%	31.9B
BEONE MEDICINES AG	+3.02%	+6.47%	+19.55%	+62.04%	31.12B
CELLTRION, INC.	-4.16%	-2.58%	+8.94%	+25.31%	23.77B
ASCENDIS PHARMA A/S	-0.47%	+13.84%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+0.37%	+16.41%	+69.00%	+125.77%	15.05B
EUROFINS SCIENTIFIC SE	-0.67%	+7.69%	+13.10%	+20.99%	13.74B
IONIS PHARMACEUTICALS, INC.	-0.71%	+7.52%	+106.53%	+98.49%	13.42B
Average	-0.15%	+9.14%	+80.03%	+116.54%	25.57B
Weighted average by Cap.	+0.10%	+8.71%	+91.90%	+137.24%